HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Autophagic degradation of farnesylated prelamin A as a therapeutic approach to lamin-linked progeria.

Abstract
Farnesylated prelamin A is a processing intermediate produced in the lamin A maturation pathway. Accumulation of a truncated farnesylated prelamin A form, called progerin, is a hallmark of the severe premature ageing syndrome, Hutchinson-Gilford progeria. Progerin elicits toxic effects in cells, leading to chromatin damage and cellular senescence and ultimately causes skin and endothelial defects, bone resorption, lipodystrophy and accelerated ageing. Knowledge of the mechanism underlying prelamin A turnover is critical for the development of clinically effective protein inhibitors that can avoid accumulation to toxic levels without impairing lamin A/C expression, which is essential for normal biological functions. Little is known about specific molecules that may target farnesylated prelamin A to elicit protein degradation. Here, we report the discovery of rapamycin as a novel inhibitor of progerin, which dramatically and selectively decreases protein levels through a mechanism involving autophagic degradation. Rapamycin treatment of progeria cells lowers progerin, as well as wild-type prelamin A levels, and rescues the chromatin phenotype of cultured fibroblasts, including histone methylation status and BAF and LAP2alpha distribution patterns. Importantly, rapamycin treatment does not affect lamin C protein levels, but increases the relative expression of the prelamin A endoprotease ZMPSTE24. Thus, rapamycin, an antibiotic belonging to the class of macrolides, previously found to increase longevity in mouse models, can serve as a therapeutic tool, to eliminate progerin, avoid farnesylated prelamin A accumulation, and restore chromatin dynamics in progeroid laminopathies.
AuthorsV Cenni, C Capanni, M Columbaro, M Ortolani, M R D'Apice, G Novelli, M Fini, S Marmiroli, E Scarano, N M Maraldi, S Squarzoni, S Prencipe, G Lattanzi
JournalEuropean journal of histochemistry : EJH (Eur J Histochem) Vol. 55 Issue 4 Pg. e36 (Oct 19 2011) ISSN: 2038-8306 [Electronic] Italy
PMID22297442 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-Bacterial Agents
  • Chromatin
  • Lamin Type A
  • Nuclear Proteins
  • Protein Precursors
  • prelamin A
  • Sirolimus
Topics
  • Anti-Bacterial Agents (pharmacology)
  • Autophagy (drug effects)
  • Blotting, Western
  • Cells, Cultured
  • Child
  • Chromatin (metabolism)
  • Fibroblasts (drug effects)
  • Humans
  • Lamin Type A
  • Nuclear Envelope (drug effects)
  • Nuclear Proteins (metabolism)
  • Prenylation
  • Progeria (pathology)
  • Protein Precursors (metabolism)
  • Sirolimus (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: